Merck sac-TMT early-stop headline, flagged and unverified in detail. Endpoints News reported on October 23 that a trial of Merck and Kelun-Biotech’s TROP2 antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) was stopped early. The full article was not accessible in this run, so which trial, in which direction and on what data cannot be verified here, and no figure is reported. What is verifiable is the calendar: Merck presents sac-TMT late-breaking data at ESMO on October 25 (OptiTROP-Lung04 survival) and October 26 (TroFuse-005 in endometrial cancer, which met both primary endpoints at a May 2026 interim analysis), and Kelun reported Phase 2 sac-TMT plus Keytruda data in first-line cisplatin-ineligible bladder cancer at ESMO on October 24, with 63 percent grade 3 or higher treatment-related adverse events and support for a global Phase 3, TroFuse-055. Source: Endpoints News headline, October 23, 2026 (grade C, single source, detail unverified); Merck ESMO program release and Kelun-Biotech release, October 2026.
Voyager chief executive steps down, Insmed adds a board member. Endpoints News reported on October 23 that Al Sandrock will step down as chief executive of Voyager Therapeutics and that Insmed has added Paul Hudson, the former Sanofi chief executive, to its board. No successor or transition terms were in the accessible text. Source: Endpoints News, October 23, 2026.
Dealmaking cooled in the third quarter. Endpoints News reported on October 23 that biotech dealmakers pulled back in the third quarter, a backdrop that makes this week’s upfront-heavy exceptions (Gilead’s $1.275 billion PepStar payment on October 22, Roche’s ZW209 license) read as selectivity rather than a broad reopening. No aggregate figure was in the accessible text, so none is reported. Source: Endpoints News, October 23, 2026.
Most European-approved cancer drugs lack high clinical benefit, analysis finds. STAT reported on October 23 on an analysis finding that most cancer drugs approved by European regulators do not score as high clinical benefit on standard scales. The item is logged for the pricing and health-technology-assessment file: benefit-scale scores feed directly into European price negotiations. Source: STAT, October 23, 2026.
Warp Sciences emerges from stealth. Endpoints News reported on October 23 that Warp Sciences, founded by a former OpenAI science chief and technology veterans, has emerged from stealth. No financing figure or program was in the accessible text, so the item is logged rather than written up. Source: Endpoints News, October 23, 2026.